Sanctuary Advisors LLC bought a new stake in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA – Free Report) in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 21,614 shares of the company’s stock, valued at approximately $449,000.
Other institutional investors also recently made changes to their positions in the company. Blue Trust Inc. grew its holdings in shares of Intellia Therapeutics by 1,664.3% during the second quarter. Blue Trust Inc. now owns 1,482 shares of the company’s stock valued at $33,000 after purchasing an additional 1,398 shares during the last quarter. EverSource Wealth Advisors LLC grew its holdings in shares of Intellia Therapeutics by 763.5% during the second quarter. EverSource Wealth Advisors LLC now owns 1,753 shares of the company’s stock valued at $39,000 after purchasing an additional 1,550 shares during the last quarter. First Horizon Advisors Inc. grew its holdings in shares of Intellia Therapeutics by 22.1% during the second quarter. First Horizon Advisors Inc. now owns 2,604 shares of the company’s stock valued at $58,000 after purchasing an additional 472 shares during the last quarter. GAMMA Investing LLC grew its holdings in shares of Intellia Therapeutics by 1,322.0% during the second quarter. GAMMA Investing LLC now owns 2,645 shares of the company’s stock valued at $59,000 after purchasing an additional 2,459 shares during the last quarter. Finally, EntryPoint Capital LLC grew its holdings in shares of Intellia Therapeutics by 61.1% during the first quarter. EntryPoint Capital LLC now owns 4,122 shares of the company’s stock valued at $113,000 after purchasing an additional 1,563 shares during the last quarter. 88.77% of the stock is owned by institutional investors.
Insider Activity
In other news, CAO Michael P. Dube sold 2,012 shares of the stock in a transaction on Wednesday, October 2nd. The stock was sold at an average price of $19.01, for a total transaction of $38,248.12. Following the completion of the sale, the chief accounting officer now owns 47,012 shares in the company, valued at approximately $893,698.12. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 3.00% of the company’s stock.
Wall Street Analysts Forecast Growth
View Our Latest Stock Report on Intellia Therapeutics
Intellia Therapeutics Price Performance
NTLA opened at $20.58 on Thursday. The company has a market capitalization of $1.99 billion, a price-to-earnings ratio of -3.84 and a beta of 1.76. Intellia Therapeutics, Inc. has a 1-year low of $17.09 and a 1-year high of $34.87. The business has a 50 day moving average price of $21.10 and a two-hundred day moving average price of $23.03.
Intellia Therapeutics (NASDAQ:NTLA – Get Free Report) last released its earnings results on Thursday, August 8th. The company reported ($1.52) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.23) by ($0.29). The business had revenue of $7.00 million during the quarter, compared to analysts’ expectations of $19.68 million. During the same period last year, the business earned ($1.40) EPS. Intellia Therapeutics’s revenue for the quarter was down 48.5% compared to the same quarter last year. Equities analysts expect that Intellia Therapeutics, Inc. will post -5.22 EPS for the current fiscal year.
Intellia Therapeutics Company Profile
Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.
Featured Stories
- Five stocks we like better than Intellia Therapeutics
- Dividend King Proctor & Gamble Is A Buy On Post-Earnings Weakness
- Taiwan Semiconductor Stock: Buy Now or Wait for Earnings?
- What Investors Must Know About Over-the-Counter (OTC) Stocks
- Abbott’s Growth and Dividends Make It a Smart Portfolio Pick
- Investing in the High PE Growth Stocks
- Citigroup Faces Growing Troubles: Could the Industry Be at Risk?
Receive News & Ratings for Intellia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.